[{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"ClinSearch | CRM Biometrics | Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Teikoku Seiyaku \/ ClinSearch | CRM Biometrics | Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Seiyaku \/ ClinSearch | CRM Biometrics | Clinigen Group"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"ClinSearch | SocraTec R&D GmbH | SocraMetrics GmbH | CRM Biometrics | Clinigen Clinical Supplies Management","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TK-254RX","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ ClinSearch | SocraTec R&D GmbH | SocraMetrics GmbH | CRM Biometrics | Clinigen Clinical Supplies Management","highestDevelopmentStatusID":"6","companyTruncated":"Teikoku Seiyaku \/ ClinSearch | SocraTec R&D GmbH | SocraMetrics GmbH | CRM Biometrics | Clinigen Clinical Supplies Management"}]

Find Clinical Drug Pipeline Developments & Deals by Teikoku Seiyaku

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Study Phase : Phase III

                          Sponsor : Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contusions.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 11, 2025

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 11, 2025

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Study Phase : Phase III

                          Sponsor : CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ankle Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 12, 2025

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Lead Product(s) : TK-254RX

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : ClinSearch | SocraTec R&D GmbH | SocraMetrics GmbH | CRM Biometrics | Clinigen Clinical Supplies Management

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : TK-254RX is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          September 18, 2023

                          Lead Product(s) : TK-254RX

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : ClinSearch | SocraTec R&D GmbH | SocraMetrics GmbH | CRM Biometrics | Clinigen Clinical Supplies Management

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Soft Tissue Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 01, 2021

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase II

                          Sponsor : ClinSearch | CRM Biometrics | Clinigen Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ankle Injuries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 06, 2016

                          Lead Product(s) : Esflurbiprofen

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank